Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

Related Citations for PubMed (Select 15004264)

1.

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.

Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM.

Nephrol Dial Transplant. 2004 May;19(5):1174-81. Epub 2004 Mar 5.

2.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R.

N Engl J Med. 2003 Jul 31;349(5):446-56.

3.

Mortality risk among hemodialysis patients receiving different vitamin D analogs.

Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc.

Kidney Int. 2006 Nov;70(10):1858-65. Epub 2006 Oct 4.

PMID:
17021609
4.
5.

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.

Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D.

Kidney Int. 2003 Apr;63(4):1483-90.

PMID:
12631365
6.

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.

J Nephrol. 2009 Jan-Feb;22(1):59-68.

PMID:
19229819
7.

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48-54.

PMID:
9808143
8.

Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.

Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram MM.

Kidney Int Suppl. 2010 Aug;(117):S33-6. doi: 10.1038/ki.2010.191.

11.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
12.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
14.

Vitamin D analogues for the management of secondary hyperparathyroidism.

Martin KJ, González EA.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34-40. Review.

PMID:
11689385
15.

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.

Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G.

Pediatr Nephrol. 2006 Oct;21(10):1434-9. Epub 2006 Aug 10.

PMID:
16900383
16.

Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.

Abdul Gafor AH, Saidin R, Loo CY, Mohd R, Zainudin S, Shah SA, Norella KC.

Nephrology (Carlton). 2009 Aug;14(5):488-92. doi: 10.1111/j.1440-1797.2008.01058.x. Epub 2009 Mar 10.

PMID:
19298641
17.

Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.

Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S61-6.

PMID:
9808145
18.

Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients.

Barton Pai A, Lin S, Arruda JA, Lau AH.

Int J Artif Organs. 2003 Jun;26(6):484-90.

PMID:
12866654
19.

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Nuijten M, Andress DL, Marx SE, Sterz R.

Curr Med Res Opin. 2009 May;25(5):1221-34. doi: 10.1185/03007990902844097 .

PMID:
19335321
20.

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

Llach F, Yudd M.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S45-50.

PMID:
11689387
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk